Mycophenolate mofetil in the treatment of retroperitoneal fibrosis

Fareeha Khalil, M. A. Mir, Rocco C. Venuto

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.

Original languageEnglish (US)
Pages (from-to)679-681
Number of pages3
JournalClinical Rheumatology
Issue number5
StatePublished - May 2008

All Science Journal Classification (ASJC) codes

  • Rheumatology


Dive into the research topics of 'Mycophenolate mofetil in the treatment of retroperitoneal fibrosis'. Together they form a unique fingerprint.

Cite this